Anthrax Vaccine Adsorbed, Adjuvanted, com-mercially known as CYFENDUS, is a preventive vaccine targeting TLR9.

the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?

Betibeglogene autotemcel, also known as Lovotibeglogene autotemcel and marketed as ZYNTEGLO, is an intravenous injection developed by bluebird bio, Inc.

Dostarlimab gxly, trade name JEMPERLI, is a monoclonal antibody targeting PD-1, originally discovered by AnaptysBio, Inc., and signed a cooperation and exclusive license agreement with TESARO, Inc. (a GSK subsidiary) in March 2014.

Iptacopan, also known as LNP023, is the first oral small moleculecompletion factor B (CFB) inhibitor developed by Novartis Pharma AG.

PRGN-2012 is a therapeutic vaccine that achieves therapeutic effects through immune stimulation.

Ritlecitinib, trade name LITFULO, is a small molecule drug targeting JAK3 and TEC (see Figure 2-9 for molecular structure).

Anaprazole Sodium is a small molecule proton pump inhibitor (PPI) developed by Beijing Sihuan Pharmaceutical Co. Ltd., approved by NMPA on June 21, 2023, for the treatment of duodenal ulcers.

Delandistrogen moxeparvovec, also known as SRP-9001, trade name ELEVIDYS, is a kind of Adeno-associated virus gene therapy targeting micro dystrophin.

The current research focus of the drug is to evaluate the efficacy of the drug in patients with severe autoimmune diseases.

Vorolanib is a new generation of multi target kinase inhibitors with a completely new chemical structure.

TAK-279, which is a highly selective inhibitor of TYK2 enzymatic activity.